Abstract: A disposable highly-protective oral-nasal mask comprises a fixing part. A notch is formed in the portion, corresponding to an oral cavity, of the fixing part. An oral cavity coverage part is arranged at the notch, corresponding to the oral cavity, of the fixing part, and is detachably connected to the fixing part. A first fold part with upward external folds is further arranged on the oral cavity coverage part. A second fold part with downward external folds is arranged on a nasal cavity coverage part. Two easily deformed components are located in accommodating cavities which are formed in the fixing part in one-to-one correspondence with the easily deformed components. Both accommodating cavities are arranged in the length direction of the fixing part. One accommodating cavity is located between the oral cavity coverage part and the nasal cavity coverage part, and the other accommodating cavity is located above the nasal cavity coverage part.

Abstract: The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.

Abstract: The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.

Abstract: The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.

Abstract: The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.

Abstract: The present invention is directed to analgesic Clostridial neurotoxin derivatives comprising polypeptides having a long-lasting SNARE protein-selective endopeptidase activity. These derivatives selectively bind to and are internalized by non-neuronal cells secreting cytokines or sensory neurons in preference to motor neurons or autonomic neurons. The invention is also directed to nucleic acid constructs encoding such polypeptides, and methods of making such derivatives and nucleic acid constructs, and methods of treating pain, such as chronic pain, by administering such derivatives to a patient suffering from, or at risk of suffering from such pain.